Cardiovascular Disease Doctors in Leetsdale, PA Accepting Medicare
4 Cardiovascular Disease doctors found. Showing 1 - 4
 Dr. Robert S Nitzberg, MD Internal Medicine - Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 12 Quaker Village Shopping Ctr, Ohio River Blvd Ste 2, Leetsdale, PA 15056 Phone: 724-773-4502 Fax: 412-749-6787 |
Jasvinder S Sandhu, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 12 Quaker Village Shopping Ctr, Ohio River Blvd Ste 2, Leetsdale, PA 15056 Phone: 724-773-4502 Fax: 412-749-6787 |
Dr. Stephen E Tunick, MD Internal Medicine - Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: Qv Shopping Center, Suite 2a Ohio River Blvd, Leetsdale, PA 15056 Phone: 724-773-4502 Fax: 412-749-6787 |
Dr. Michael J. Malkowski, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 12 Quaker Village Shopping Ctr, Ohio River Blvd Ste 2, Leetsdale, PA 15056 Phone: 724-773-4502 Fax: 412-749-6787 |
News Archive
Researchers identify fasting plasma glucose and insulin as key biomarkers for weight loss
Researchers from the Department of Nutrition, Exercise and Sports at the University of Copenhagen today announced the findings from a weight loss biomarker study published in the American Journal of Clinical Nutrition.
Maryland insurers agree to delay deadline for Jan. 1 enrollment
For consumers seeking coverage on the state's health exchange, Maryland's insurers will extend the enrollment deadline from Dec. 23 to Dec. 27. Rhode Island also plans to extend its deadline. Meanwhile, news outlets offer updates from Texas, Connecticut, California, Minnesota, Wisconsin, Colorado and Washington.
Cornerstone Pharmaceuticals includes Mary Crowley Research Centers in CPI-613 clinical trials
Cornerstone Pharmaceuticals, Inc. today announced the addition of Mary Crowley Cancer Research Centers to its roster of sites for its ongoing Phase I/II clinical trials of its first-in-class anti-cancer agent, CPI-613. Cornerstone is a leader in the discovery and development of cancer therapies that capitalize upon and disrupt the unique metabolic processes of cancer cells.
Bruker showcases innovative high-performance systems and high-value analytical solutions at Pittcon 2017
Bruker (NASDAQ: BRKR) is showcasing a selection of innovative high-performance systems and high-value analytical solutions at Pittcon 2017 (www.pittcon.org), with an emphasis on pharma and applied markets, as well as on nano-materials research and microscopy.
› Verified 5 days ago